PMID- 36451670
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221202
IS  - 2287-3651 (Print)
IS  - 2287-366X (Electronic)
IS  - 2287-3651 (Linking)
VI  - 11
IP  - 3
DP  - 2022 Sep
TI  - Identifying immunodominant multi-epitopes from the envelope glycoprotein of the 
      Lassa mammarenavirus as vaccine candidate for Lassa fever.
PG  - 249-263
LID - 10.7774/cevr.2022.11.3.249 [doi]
AB  - PURPOSE: Lassa fever is a zoonotic acute viral hemorrhagic disease caused by 
      Lassa virus (LASV). There is currently no licensed vaccine for the prevention of 
      the disease. This study is aimed at discovering immunodominant epitopes from the 
      envelope glycoprotein of the Lassa mammarenavirus and designing of a 
      multi-epitope vaccine candidate (VC). MATERIALS AND METHODS: The amino acid 
      sequences of the envelope glycoprotein of 26 strains of LASV from five countries 
      were selected. After evaluation for antigenicity, immunogenicity, allergenicity, 
      and toxicity, immunodominant CD8, CD4, and linear B lymphocytes were also 
      selected. The selected epitopes were modelled and a molecular docking with the 
      appropriate major histocompatibility complex (MHC) proteins was performed. Using 
      an adjuvant and linkers, a multi-epitope VC was designed. The VC was evaluated 
      for its physicochemical and immunological properties and structurally refined, 
      validated, and mutated (disulphide engineering). The complex formed by the VC and 
      the toll-like receptor-4 receptor was subjected to molecular dynamic simulation 
      (MDS) followed by in silico cloning in a plasmid vector. RESULTS: A VC with 203 
      sequences, 22.13 kDa weight, isoelectric point of 9.85 (basic), instability index 
      value of 27.62, aliphatic index of 68.87, and GRAVY value of -0.455 (hydrophilic) 
      emerged. The VC is predicted to be non-allergenic with antigenicity, MHC I 
      immunogenicity, and solubility upon overexpression values of 0.81, 2.04, and 0.86 
      respectively. The VC also has an estimated half-life greater than 10 hours in 
      Escherichia coli and showed stability in all the parameters of MDS. CONCLUSION: 
      The VC shows good promise in the prevention of Lassa fever but further tests are 
      required to validate its safety and efficacy.
CI  - (c) Korean Vaccine Society.
FAU - Rowaiye, Adekunle Babajide
AU  - Rowaiye AB
AUID- ORCID: 0000-0002-8773-5944
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
FAU - Nwonu, Ezinne Janefrances
AU  - Nwonu EJ
AUID- ORCID: 0000-0001-8392-9170
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
FAU - Asala, Titilayo Mercy
AU  - Asala TM
AUID- ORCID: 0000-0003-3464-2936
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
FAU - Ogu, Amoge Chidinma
AU  - Ogu AC
AUID- ORCID: 0000-0003-3461-2737
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
FAU - Bur, Doofan
AU  - Bur D
AUID- ORCID: 0000-0001-7625-7118
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
FAU - Chukwu, Chimaobi
AU  - Chukwu C
AUID- ORCID: 0000-0003-2411-0290
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
FAU - Oli, Angus Nnamdi
AU  - Oli AN
AUID- ORCID: 0000-0001-8519-2555
AD  - Department of Microbiology and Biotechnology, Faculty of Pharmaceutical Sciences, 
      Nnamdi Azikiwe University, Awka, Nigeria.
FAU - Agbalalah, Tarimoboere
AU  - Agbalalah T
AUID- ORCID: 0000-0002-5875-4126
AD  - National Biotechnology Development Agency, Abuja, Nigeria.
AD  - Department of Anatomy, Baze University, Abuja, Nigeria.
LA  - eng
PT  - Journal Article
DEP - 20220930
PL  - Korea (South)
TA  - Clin Exp Vaccine Res
JT  - Clinical and experimental vaccine research
JID - 101592344
PMC - PMC9691867
OTO - NOTNLM
OT  - Envelope protein
OT  - Epitopes
OT  - Lassa virus
OT  - Major histocompatibility complex
OT  - Vaccine candidate
COIS- No potential conflict of interest relevant to this article was reported.
EDAT- 2022/12/02 06:00
MHDA- 2022/12/02 06:01
PMCR- 2022/09/01
CRDT- 2022/12/01 02:24
PHST- 2022/05/26 00:00 [received]
PHST- 2022/07/26 00:00 [accepted]
PHST- 2022/12/01 02:24 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/02 06:01 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - 10.7774/cevr.2022.11.3.249 [doi]
PST - ppublish
SO  - Clin Exp Vaccine Res. 2022 Sep;11(3):249-263. doi: 10.7774/cevr.2022.11.3.249. 
      Epub 2022 Sep 30.